DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-3.3%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.58B
AUM Growth
+$2.58B
(+20%)
Cap. Flow
+$513M
Cap. Flow
% of AUM
19.91%
Top 10 Holdings %
Top 10 Hldgs %
46.08%
Holding
70
New
15
Increased
18
Reduced
13
Closed
6
Top Buys
| 1 |
Guardant Health
GH
|
$75.6M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$54.8M |
| 3 |
Axsome Therapeutics
AXSM
|
$52.9M |
| 4 |
Apogee Therapeutics
APGE
|
$51.4M |
| 5 |
NovoCure
NVCR
|
$40.4M |
Top Sells
| 1 |
Immunovant
IMVT
|
$101M |
| 2 |
Structure Therapeutics
GPCR
|
$36.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$14.5M |
| 4 |
Insmed
INSM
|
$12.6M |
| 5 |
INZY
Inozyme Pharma
INZY
|
$9.16M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $152M | 5.85% | 6,000,000 -500,000 | -8% | -$12.6M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $147M | 5.69% | 1,138,045 -111,955 | -9% | -$14.5M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $135M | 5.23% | 2,600,000 +1,051,748 | +68% | +$54.8M |
|
4
Ionis Pharmaceuticals
IONS
$6.79B
| $129M | 4.96% | 2,834,069 | – | – |
|
|
5
Guardant Health
GH
$8.41B
| $120M | 4.63% | 4,050,000 +2,550,000 | +170% | +$75.6M |
|
|
6
Immunovant
IMVT
$2.56B
| $107M | 4.15% | 2,797,955 -2,623,375 | -48% | -$101M |
|
7
Alkermes
ALKS
$4.78B
| $106M | 4.11% | 3,800,000 +800,000 | +27% | +$22.4M |
|
8
Dynavax Technologies
DVAX
$1.19B
| $99.8M | 3.85% | 6,756,956 +199,140 | +3% | +$2.94M |
|
|
9
Structure Therapeutics
GPCR
$1.11B
| $96.6M | 3.73% | 1,915,000 -731,782 | -28% | -$36.9M |
|
10
Pliant Therapeutics
PLRX
$101M
| $95.4M | 3.68% | 5,500,000 +1,450,000 | +36% | +$25.1M |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $82M | 3.16% | 3,546,435 | – | – |
|
|
12
Axsome Therapeutics
AXSM
$6.05B
| $79.7M | 3.08% | 1,140,745 +756,545 | +197% | +$52.9M |
|
|
BCYC
13
Bicycle Therapeutics
BCYC
$511M
| $70.1M | 2.71% | 3,490,506 +671,461 | +24% | +$13.5M |
|
14
Travere Therapeutics
TVTX
$1.56B
| $65.9M | 2.54% | 7,370,000 | – | – |
|
15
Intellia Therapeutics
NTLA
$1.22B
| $63.2M | 2.44% | 2,000,000 +1,164,554 | +139% | +$36.8M |
|
16
Editas Medicine
EDIT
$231M
| $55.4M | 2.14% | 7,101,935 +3,648,191 | +106% | +$28.5M |
|
17
Geron
GERN
$893M
| $54.5M | 2.1% | 25,700,000 +1,529,034 | +6% | +$3.24M |
|
|
VRNA
18
Verona Pharma
VRNA
$9.16B
| $52M | 2.01% | 3,187,415 | – | – |
|
|
19
Apogee Therapeutics
APGE
$2.17B
| $51.4M | 1.98% | +2,414,373 | New | +$51.4M |
|
20
Pacific Biosciences
PACB
$393M
| $50.1M | 1.93% | 6,000,000 +4,548,799 | +313% | +$38M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $45.5M | 1.75% | 2,963,267 +1,683,765 | +132% | +$25.8M |
|
|
22
NovoCure
NVCR
$1.38B
| $40.4M | 1.56% | +2,500,000 | New | +$40.4M |
|
23
HilleVax
HLVX
$105M
| $39M | 1.51% | +2,900,000 | New | +$39M |
|
24
Repare Therapeutics
RPTX
$71.7M
| $37.1M | 1.43% | 3,067,731 +340,125 | +12% | +$4.11M |
|
|
AGEN
25
Agenus
AGEN
$133M
| $35.8M | 1.38% | 31,697,539 +1,697,539 | +6% | +$1.92M |
|